Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MacroGenics, Inc. (MGNX : NSDQ)

• Company Description    MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. Number of Employees: 427

• Price / Volume Information    Yesterday's Closing Price: $4.31 Daily Weekly Monthly 20 Day Moving Average: 927,548 shares Shares Outstanding: 61.33 (millions) Market Capitalization: $264.35 (millions) Beta: 2.13 52 Week High: $32.81 52 Week Low: $3.92 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -47.57% -42.78% 12 Week -57.54% -55.29% Year To Date -73.15% -68.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9704 MEDICAL CENTER DRIVE - Rockville,MD 20850 USA ph: 301-251-5172 fax: 301-251-5321 None http://www.macrogenics.com

• General Corporate Information    Officers Scott Koenig - Chief Executive Officer;President and Director James Karrels - Senior Vice President; Chief Financial Officer and Lynn Cilinski - Vice President; Controller and Treasurer Paulo Costa - Director Karen Ferrante - Director Peer Information MacroGenics, Inc. (BJCT) MacroGenics, Inc. (CADMQ) MacroGenics, Inc. (APNO) MacroGenics, Inc. (UPDC) MacroGenics, Inc. (IMTIQ) MacroGenics, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 556099109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 61.33 Most Recent Split Date: (:1) Beta: 2.13 Market Capitalization: $264.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.96 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.15 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.48 Price/Cash Flow: - Price / Sales: 3.69 EPS Growth vs. Year Ago Period: -20.00% vs. Previous Quarter: -13.68% Sales Growth vs. Year Ago Period: -34.24% vs. Previous Quarter: -21.53% ROE 03/31/22 - -84.52 12/31/21 - -67.34 09/30/21 - -46.52 ROA 03/31/22 - -61.00 12/31/21 - -50.89 09/30/21 - -35.82 Current Ratio 03/31/22 - 3.25 12/31/21 - 3.75 09/30/21 - 4.86 Quick Ratio 03/31/22 - 3.18 12/31/21 - 3.69 09/30/21 - 4.80 Operating Margin 03/31/22 - -303.19 12/31/21 - -260.97 09/30/21 - -126.03 Net Margin 03/31/22 - -303.19 12/31/21 - -260.97 09/30/21 - -126.03 Pre-Tax Margin 03/31/22 - -303.19 12/31/21 - -260.97 09/30/21 - -126.03 Book Value 03/31/22 - 2.91 12/31/21 - 3.91 09/30/21 - 4.76 Inventory Turnover 03/31/22 - 0.55 12/31/21 - 0.50 09/30/21 - 0.41 Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©